{
    "symbol": "RDY",
    "slug": "rdy",
    "display_name": "RDY",
    "category": "stocks",
    "region": "India",
    "description": null,
    "url": "https://finscans.com/asset/rdy",
    "lang": "en",
    "as_of": "2026-07-22T15:10:41+00:00",
    "stats_30d": {
        "total_signals": 1,
        "bullish": 0,
        "bearish": 1,
        "neutral": 0,
        "explicit": 1,
        "inferred": 0,
        "avg_impact": 8,
        "avg_confidence": 85,
        "last_signal_at": "2026-07-22 15:22:02",
        "article_count": 1
    },
    "top_catalysts": [
        {
            "text": "Trump administration explicitly renewed tariff threat on Indian generic drug imports",
            "count": 1
        }
    ],
    "top_risk_factors": [
        {
            "text": "Congressional pushback or pharma lobby could delay tariffs",
            "count": 1
        },
        {
            "text": "Dr. Reddy’s could accelerate US manufacturing plans to circumvent duties",
            "count": 1
        }
    ],
    "recent_signals": [
        {
            "signal_at": "2026-07-22 15:22:02",
            "sentiment": "Bearish",
            "impact_score": 8,
            "confidence_score": 85,
            "mention_type": "explicit",
            "timeframe": "short-term",
            "region": "India",
            "reasoning": "Dr. Reddy’s Laboratories fell 4.2% as the renewed US tariff threat directly threatens its largest revenue source. The company derives over 40% of income from the US generics market, where its pricing advantage would evaporate under new duties. The move signals margin compression and potential lost contracts to domestic US or other non‑tariffed competitors.",
            "article": {
                "title": "Trump Renews Tariff Threat on Indian Drugmakers, Dr. Reddy’s Slides",
                "url": "https://finscans.com/news/trump-renews-tariff-threat-on-indian-drugmakers-dr-reddys"
            }
        }
    ]
}